AIM: To evaluate the effect of microfiltrating the extract of Sophora japonica L. by inorganic ceramic membrane. METHODS: The extract of Sophora japonica L. was processed by inorganic ceramic membrane, and the whole solid, effective ingredinent and flux of mebrane were examined. RESULTS: The extract of Sophora japonica L. became clear after microfiltration. The decreasing rate of the whole solid was 27.88%, the metastasis rate of the effective ingredient was 78.26, and the increasing rate of the effective ingredient was 8.48%. CONCLUSION: The microfiltration of inorganic ceramic membrane can improve the qualitry of extract of Sophora japonica L. refinery effect.

AIM:To study the chemical constituents of Lysimachia clethroide Duby. METHODS:Chromatographic techniques,including MS and NMR,were used to isolate and purify the constituents based on column chromatography separation on silica gel,Sephadex LH-20 and Semipreparative RP-HPLC. RESULTS:Eleven flavonoids were obtained and elucidated as: kaempferol (1),kaempferol 3-O-?-D-glucopyranoside (2),kaempferol 3-O-?-D-galactoside (3),kaempferol 3-O-?-D-(6″-p-coumaroyl)-glucopyranoside (4),quercetin (5),Isorhamnetin (6) ,quercetin 3-O-?-D-galactoside (7),quercetin 3′-methoxy-3-O-?-D-galactoside (8),quercetin 3-O-?-D-(6″-p-coumaroyl)-galactoside (9),4′-methoxy-5,6-dihydroxyisoflavone-7-O-?-D-glucopyranoside (10),7-O-glucosyl liquiritigenin (11). CONCLUSION: Compounds 3,6 were isolated from this plant and compounds 8-11 were isolated from this genus for the first time.

OBJECTIVETo evaluate safety and immunogenicity of inactivated hepatitis A vaccine in HBsAg carriers and healthy children.

METHODSOne hundred and twenty-one healthy children and ten HBsAg carriers, aged 1-10 years HAV susceptible were enrolled in the study. The inactivated hepatitis A vaccine was produced by Tangshan Biogenetic Company. The dosage of the vaccine was 1000 U/Dosage and 500 U/Dosage. The vaccination schedule was six month apart for two injections. The serum anti-HAV level was detected with EIA at one month after first injection and at one and six month after the booster injection, respectively.

RESULTSThe anti-HAV appeared in all the children. One month after the booster injection, the serum anti-HAV level in children vaccinated 500 U/Dosage was 4684.9 mIU and 4535.6 mIU, respectively and in the children vaccinated 1000 U/Dosage, 5399.8 mIU and 7347.1 mIU, respectively. The anti-HAV level was not statistically different between the two groups of children. There was no adverse reaction after the vaccination. The anti-HAV level was still high one year after first injection.

CONCLUSIONSThe data indicated that the safety and immunogenicity of the domestic inactivated hepatitis A vaccine were excellent in both groups of children.

Child ; Child, Preschool ; Hepatitis A Antibodies ; blood ; Hepatitis A Vaccines ; immunology ; Hepatitis B Surface Antigens ; blood ; Humans ; Immunization ; Infant ; Vaccines, Inactivated ; immunology